Oncology News and Research

RSS
Hippocampal avoidance during whole-brain radiotherapy reduces risk of cognitive decline

Hippocampal avoidance during whole-brain radiotherapy reduces risk of cognitive decline

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

FDA targets 465 websites that sell potentially dangerous, unapproved drugs

FDA targets 465 websites that sell potentially dangerous, unapproved drugs

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Drugs approved for breast cancer treatment are effective and well tolerated in men

Construction is underway for second proton therapy system at Siteman Cancer Center

Construction is underway for second proton therapy system at Siteman Cancer Center

New discovery may lead to better treatment options for pancreatic cancer patients

New discovery may lead to better treatment options for pancreatic cancer patients

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Study: Targeting specific genomic mutation in breast cancer improves survival

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Targeted drug and hormone therapy combination extends breast cancer survival

Targeted drug and hormone therapy combination extends breast cancer survival

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Study findings could set new standard of care for advanced anal cancer

Study findings could set new standard of care for advanced anal cancer

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.